如何治疗儿童和青少年慢性髓系白血病
儿童和青少年慢性髓系白血病(CML)罕见,酪氨酸激酶抑制剂(TKI)显著改善预后,但存在生长减速、长期不良反应未知及无治疗缓解角色待定等挑战。儿童CML管理多从成人指南外推,但生物学、分子及宿主因素不同需差异化治疗。自2003年伊马替尼获批后,达沙替尼、尼洛替尼和博舒替尼三种二代TKI获批,扩大了治疗选择但也增加了决策复杂性。本文通过3个常见病例讨论挑战与推荐管理。
要点
- 儿童CML罕见,TKI治疗改善预后但生长减速和长期不良反应未知。
- 儿童CML管理常从成人指南外推,但生物学和宿主因素不同需不同方法。
- 自2003年伊马替尼后,达沙替尼、尼洛替尼和博舒替尼获批扩大选择。
核心结论
- 儿童CML因TKI使结局显著改善,但生长减速、长期不良反应未知及无治疗缓解角色待定仍是挑战。
- 儿童CML管理常从成人指南外推,但生物学、分子及宿主因素不同需不同治疗。
- 多种二代TKI获批扩大治疗选择,但也增加治疗决策复杂性并引发长期疗效和安全性问题。
研究设计与样本
- 本文为综述,通过3个儿童CML常见病例讨论挑战和相关问题及推荐管理。
主要发现
- 儿童CML罕见,TKI治疗使结局显著改善但存在生长减速和长期不良反应未知等挑战。
- 儿童CML与成人CML在生物学、分子及宿主因素上不同,需不同治疗。
- 自2003年伊马替尼获批后,达沙替尼、尼洛替尼和博舒替尼三种二代TKI获批。
关键数值与推荐
- 儿童CML管理常从成人指南外推。
- 2003年第一代伊马替尼获批用于儿童CML。
- 达沙替尼、尼洛替尼和博舒替尼均为二代TKI并已获批。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic myeloid leukemia (CML) is rare in children and adolescents. Although outcomes have dramatically improved owing to tyrosine kinase inhibitors (TKIs) in the last 2 decades, there are still many challenges related to the management of pediatric CML, including the impact of TKIs on growth deceleration and unknown long-term adverse effects as well as defining the role of treatment-free remission. Unlike adult CML, which is driven by evidence-based guidelines, management of pediatric CML is often extrapolated from adult guidelines. However, pediatric CML differs from adult CML in many ways, presenting with different biological; molecular; and, most importantly, host factors that make it necessary for a different treatment approach. After the initial approval of first-generation imatinib for pediatric CML in 2003, 3 TKIs, all second-generation TKIs, have been approved, including dasatinib, nilotinib, and bosutinib, which have greatly expanded therapeutic options but also added complexity to treatment determination. The expanded treatment options also call into question the treatment choice for pediatric CML, long-term efficacy, and safety profiles of these TKIs. We present 3 cases commonly encountered in pediatric CML, their challenges and relevant issues, as well as recommended managements.
引用
- Chen J, Suttorp M, Hijiya N, et al. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2026. PMID: 40132166. doi:10.1182/blood.2024026514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。